A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT06520098 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

FED

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Venetoclax
DRUG: Ibrutinib, Acalabrutinib, Zanubrutinib

Sponsor

VA Office of Research and Development